Biogen Inc – Strategy, SWOT and Corporate Finance Report

Biogen Inc – Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360Ëš view of the company.

Biogen Inc (Biogen) is a biopharmaceutical company that discovers, develops and delivers drugs for the treatment of neurological and neurodegenerative diseases. The company’s marketed products include Avonex (interferon beta-1a), Tysabri (natalizumab), Tecfidera (dimethyl fumarate), Fampyra (prolonged-release fampridine tablets) and Plegridy (peginterferon beta-1a) for the treatment of multiple sclerosis (MS); Spinraza (nusinersen) for spinal muscular atrophy (SMA); and Fumaderm (fumaric acid esters) for severe plaque psoriasis. The company also offers biosimilars through its joint venture, Samsung Bioepis. It has several product candidates targeting various indications such as MS, Parkinson's disease, Alzheimer’s disease and idiopathic pulmonary fibrosis, and stroke among others. The company sells its products through direct sales forces, marketing groups and distributors in the Americas, Europe, Asia and other territories. Biogen is headquartered in Cambridge, Massachusetts, the US.

Scope

Detailed information on Biogen Inc required for business and competitor intelligence needs

A study of the major internal and external factors affecting Biogen Inc in the form of a SWOT analysis

An in-depth view of the business model of Biogen Inc including a breakdown and examination of key business segments

News about Biogen Inc, such as business expansion, restructuring, and contract wins

Large number of easy-to-grasp charts and graphs that present important data and key trends

Reasons to buy

Gain understanding of Biogen Inc and the factors that influence its strategies.

Track strategic initiatives of the company and latest corporate news and actions.

Assess Biogen Inc as a prospective partner, vendor or supplier.

Support sales activities by understanding your customers' businesses better.

Stay up to date on Biogen Incs business structure, strategy and prospects.

Note: Some sections may be missing if data is unavailable for the company.

Companies mentioned

Novartis AG

Merck & Co Inc

United Neuroscience Ltd

Teva Pharmaceutical Industries Ltd

Bayer HealthCare Pharmaceuticals

Pfizer Inc

Sanofi

Dart NeuroScience LLC

Alzheon Inc

Table of Contents

Table of Contents

Table of Contents

List of Tables

List of Figures

Section 1 - About the Company

Biogen Inc - Key Facts

Biogen Inc - Key Employees

Biogen Inc - Key Employee Biographies

Biogen Inc - Major Products and Services

Biogen Inc - History

Biogen Inc - Company Statement

Biogen Inc - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Joint Venture

Section 2 Company Analysis

Company Overview

Biogen Inc - Business Description

Product Category: Biosimilars

Overview

Performance

Product Category: Multiple Sclerosis

Overview

Performance

Product Category: Others

Overview

Performance

Product Category: Spinal Muscular Atrophy

Overview

Performance

Geographical Segment: Asia

Performance

Geographical Segment: Europe

Performance

Geographical Segment: Other

Performance

Geographical Segment: US

Performance

R&D Overview

Biogen Inc - Corporate Strategy

Biogen Inc - SWOT Analysis

SWOT Analysis - Overview

Biogen Inc - Strengths

Biogen Inc - Weaknesses

Biogen Inc - Opportunities

Biogen Inc - Threats

Biogen Inc - Key Competitors

Section 3 Company Financial Ratios

Financial Ratios - Capital Market Ratios

Financial Ratios - Annual Ratios

Performance Chart

Financial Performance

Financial Ratios - Interim Ratios

Financial Ratios - Ratio Charts

Section 4 Company’s Lifesciences Financial Deals and Alliances

Biogen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Biogen Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

Biogen Inc, Recent Deals Summary

Section 5 Company’s Recent Developments

Mar 12, 2019: Biogen to sell biologics production site to Fujifilm for $890m

Mar 04, 2019: Biogen to buy gene therapy firm Nightstar Therapeutics for $800m

Mar 01, 2019: Biogen Responds to CADTH’s updated recommendation regarding coverage for SPINRAZA

Feb 28, 2019: Biogen Further Expands Presence in China with Approval of SPINRAZA (nusinersen), the First and Only Treatment for Spinal Muscular Atrophy

Jan 29, 2019: Biogen reports record revenues for both the full year and Q4 2018, $13.5 billion and $3.5 billion, respectively

Jan 07, 2019: Biogen signs two deals to address neurological disorders

Dec 06, 2018: Top Canadian researchers at the helm of pioneering Canadian Proactive Cohort Study for People Living with MS (CanProCo)

Nov 29, 2018: International Prix Galien Recognizes SPINRAZA® as Best Biotechnology Product

Nov 29, 2018: International Prix Galien Recognizes SPINRAZA® as Best Biotechnology Product

Nov 19, 2018: Biogen and Amicus win UK Prix Galien awards for rare disease medicines

Section 6 Appendix

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer

List of Tables

List of Tables

Biogen Inc, Key Facts

Biogen Inc, Key Employees

Biogen Inc, Key Employee Biographies

Biogen Inc, Major Products and Services

Biogen Inc, History

Biogen Inc, Other Locations

Biogen Inc, Subsidiaries

Biogen Inc, Joint Venture

Biogen Inc, Key Competitors

Biogen Inc, Ratios based on current share price

Biogen Inc, Annual Ratios

Biogen Inc, Annual Ratios (Cont…1)

Biogen Inc, Annual Ratios (Cont…2)

Biogen Inc, Interim Ratios

Biogen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Biogen Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

Biogen Inc, Recent Deals Summary

Currency Codes

Capital Market Ratios

Equity Ratios

Profitability Ratios

Cost Ratios

Liquidity Ratios

Leverage Ratios

Efficiency Ratios

List of Figures

List of Figures

Biogen Inc, Performance Chart (2014 – 2018)

Biogen Inc, Ratio Charts

Biogen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Biogen Inc, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019

    Pricing

Discounts available for multiple purchases.

reportstore@marketline.com
+44 20 7947 2960

Saved reports